Business & Finance
BioCryst shifts strategy toward acquiring early-stage rare disease assets following sustained profitability
Driven by Orladeyo sales, the biotechnology company plans to purchase external drugs rather than rely solely on internal development.
The short version
- BioCryst Pharmaceuticals plans to acquire external early-stage rare disease assets rather than relying solely on internal drug development.
- The strategic shift follows sustained profitability driven by its hereditary angioedema drug, Orladeyo, which has generated over $2 billion in sales since 2020.
- The company plans to target assets with smaller peak sales potential, such as $300 million, taking advantage of a gap left by larger pharmaceutical firms targeting mega-blockbuster treatments.
Key facts
- BioCryst Pharmaceuticals CEO Charlie Gayer stated that the company was profitable last year and projects increasing profitability in upcoming years.[CNBC]
- BioCryst's FDA-approved hereditary angioedema treatment, Orladeyo, has generated over $2 billion in sales since its 2020 approval, with 2026 sales projected to reach up to $645 million.[CNBC]
- BioCryst plans to acquire early-stage assets externally, remaining therapeutic-area agnostic and open to targets with peak sales around $300 million.[CNBC]
- The Richard K. Mellon Foundation committed up to $25 million to launch Rare Ventures, a venture philanthropy accelerator focused on funding treatments for seven rare conditions.[CNBC]
- RTW Managing Partner and CIO Rod Wong stated that large pharmaceutical companies are increasingly focusing on assets with peak sales of $2 billion or more, creating space for small and midsize biotech buyers.[CNBC]
What remains uncertain
- Specific external drug targets and financial terms for future BioCryst acquisitions have not been disclosed.[CNBC]